Chute, Michael; Aujla, Preetinder; Jana, Sayantan; Kassiri, Zamaneh (2019). «The Non-Fibrillar Side of Fibrosis: Contribution of the Basement Membrane, Proteoglycans, and Glycoproteins to Myocardial Fibrosis». Journal of Cardiovascular Development and Disease6 (4): 35. doi:10.3390/jcdd6040035. ISSN2308-3425.
Gräni, Christoph; Eichhorn, Christian; Bière, Loïc; Kaneko, Kyoichi; Murthy, Venkatesh L.; Agarwal, Vikram; Aghayev, Ayaz; Steigner, Michael και άλλοι. (2019). «Comparison of myocardial fibrosis quantification methods by cardiovascular magnetic resonance imaging for risk stratification of patients with suspected myocarditis». Journal of Cardiovascular Magnetic Resonance21 (1). doi:10.1186/s12968-019-0520-0. ISSN1532-429X.
Bhaskaran, Ashwin; Tung, Roderick; Stevenson, William G.; Kumar, Saurabh (2019). «Catheter Ablation of VT in Non-Ischaemic Cardiomyopathies: Endocardial, Epicardial and Intramural Approaches». Heart, Lung and Circulation28 (1): 84–101. doi:10.1016/j.hlc.2018.10.007. ISSN14439506.
«Valvular heart disease and the use of dopamine agonists for Parkinson's disease». The New England Journal of Medicine356 (1): 39–46. January 2007. doi:10.1056/NEJMoa054830. PMID17202454.
«Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists». Movement Disorders24 (1): 129–33. January 2009. doi:10.1002/mds.22385. PMID19170199.
«Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis». Archives of Neurology64 (12): 1721–6. December 2007. doi:10.1001/archneur.64.12.1721. PMID18071034.
«Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease». The Lancet. Neurology6 (9): 826–9. September 2007. doi:10.1016/S1474-4422(07)70218-1. PMID17706566.
«Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine». Mayo Clinic Proceedings74 (12): 1191–7. December 1999. doi:10.4065/74.12.1191. PMID10593346.
«Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis». Clinical Neuropharmacology29 (2): 80–6. 2006. doi:10.1097/00002826-200603000-00005. PMID16614540.
«Dopamine agonists and the risk of cardiac-valve regurgitation». The New England Journal of Medicine356 (1): 29–38. January 2007. doi:10.1056/NEJMoa062222. PMID17202453.
«3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro». Molecular Pharmacology63 (6): 1223–9. June 2003. doi:10.1124/mol.63.6.1223. PMID12761331.
«A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor». Journal of Medicinal Chemistry41 (26): 5148–9. December 1998. doi:10.1021/jm9803525. PMID9857084.
«Discriminative stimulus effects of m-chlorophenylpiperazine as a model of the role of serotonin receptors in anxiety». Life Sciences73 (11): 1347–67. August 2003. doi:10.1016/S0024-3205(03)00422-3. PMID12850497.
«5-HT2 receptor activation in the midbrain periaqueductal grey (PAG) reduces anxiety-like behaviour in mice». Behavioural Brain Research187 (1): 72–9. February 2008. doi:10.1016/j.bbr.2007.08.030. PMID17935799.
«Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease». The American Journal of Cardiology100 (9): 1442–5. November 2007. doi:10.1016/j.amjcard.2007.06.045. PMID17950805.
«Effects of L-5HTP with and without carbidopa on plasma beta-endorphin and pain perception: possible implications in migraine prophylaxis». Cephalalgia6 (3): 175–9. September 1986. doi:10.1046/j.1468-2982.1986.0603175.x. PMID2945645.
«Improving outcome of valve replacement for carcinoid heart disease». The Journal of Thoracic and Cardiovascular Surgery158 (1): 99–107.e2. July 2019. doi:10.1016/j.jtcvs.2018.09.025. PMID30527716.
«Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol». American Journal of Physiology. Heart and Circulatory Physiology288 (3): H1131-8. March 2005. doi:10.1152/ajpheart.00763.2004. PMID15498824.
«Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol». The Journal of Pharmacology and Experimental Therapeutics325 (3): 961–8. June 2008. doi:10.1124/jpet.107.135061. PMID18356487.
«Preventive effects of nutritional doses of polyphenolic molecules on cardiac fibrosis associated with metabolic syndrome: involvement of osteopontin and oxidative stress». Journal of Agricultural and Food Chemistry56 (24): 11683–7. December 2008. doi:10.1021/jf802357g. PMID19049292.
«Valvular heart disease and the use of dopamine agonists for Parkinson's disease». The New England Journal of Medicine356 (1): 39–46. January 2007. doi:10.1056/NEJMoa054830. PMID17202454.
«Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists». Movement Disorders24 (1): 129–33. January 2009. doi:10.1002/mds.22385. PMID19170199.
«Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis». Archives of Neurology64 (12): 1721–6. December 2007. doi:10.1001/archneur.64.12.1721. PMID18071034.
«Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease». The Lancet. Neurology6 (9): 826–9. September 2007. doi:10.1016/S1474-4422(07)70218-1. PMID17706566.
«Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine». Mayo Clinic Proceedings74 (12): 1191–7. December 1999. doi:10.4065/74.12.1191. PMID10593346.
«Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis». Clinical Neuropharmacology29 (2): 80–6. 2006. doi:10.1097/00002826-200603000-00005. PMID16614540.
«Dopamine agonists and the risk of cardiac-valve regurgitation». The New England Journal of Medicine356 (1): 29–38. January 2007. doi:10.1056/NEJMoa062222. PMID17202453.
«3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro». Molecular Pharmacology63 (6): 1223–9. June 2003. doi:10.1124/mol.63.6.1223. PMID12761331.
«A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor». Journal of Medicinal Chemistry41 (26): 5148–9. December 1998. doi:10.1021/jm9803525. PMID9857084.
«Discriminative stimulus effects of m-chlorophenylpiperazine as a model of the role of serotonin receptors in anxiety». Life Sciences73 (11): 1347–67. August 2003. doi:10.1016/S0024-3205(03)00422-3. PMID12850497.
«5-HT2 receptor activation in the midbrain periaqueductal grey (PAG) reduces anxiety-like behaviour in mice». Behavioural Brain Research187 (1): 72–9. February 2008. doi:10.1016/j.bbr.2007.08.030. PMID17935799.
«Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease». The American Journal of Cardiology100 (9): 1442–5. November 2007. doi:10.1016/j.amjcard.2007.06.045. PMID17950805.
«Effects of L-5HTP with and without carbidopa on plasma beta-endorphin and pain perception: possible implications in migraine prophylaxis». Cephalalgia6 (3): 175–9. September 1986. doi:10.1046/j.1468-2982.1986.0603175.x. PMID2945645.
«Improving outcome of valve replacement for carcinoid heart disease». The Journal of Thoracic and Cardiovascular Surgery158 (1): 99–107.e2. July 2019. doi:10.1016/j.jtcvs.2018.09.025. PMID30527716.
«Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol». American Journal of Physiology. Heart and Circulatory Physiology288 (3): H1131-8. March 2005. doi:10.1152/ajpheart.00763.2004. PMID15498824.
«Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol». The Journal of Pharmacology and Experimental Therapeutics325 (3): 961–8. June 2008. doi:10.1124/jpet.107.135061. PMID18356487.
«Preventive effects of nutritional doses of polyphenolic molecules on cardiac fibrosis associated with metabolic syndrome: involvement of osteopontin and oxidative stress». Journal of Agricultural and Food Chemistry56 (24): 11683–7. December 2008. doi:10.1021/jf802357g. PMID19049292.
Chute, Michael; Aujla, Preetinder; Jana, Sayantan; Kassiri, Zamaneh (2019). «The Non-Fibrillar Side of Fibrosis: Contribution of the Basement Membrane, Proteoglycans, and Glycoproteins to Myocardial Fibrosis». Journal of Cardiovascular Development and Disease6 (4): 35. doi:10.3390/jcdd6040035. ISSN2308-3425.
Gräni, Christoph; Eichhorn, Christian; Bière, Loïc; Kaneko, Kyoichi; Murthy, Venkatesh L.; Agarwal, Vikram; Aghayev, Ayaz; Steigner, Michael και άλλοι. (2019). «Comparison of myocardial fibrosis quantification methods by cardiovascular magnetic resonance imaging for risk stratification of patients with suspected myocarditis». Journal of Cardiovascular Magnetic Resonance21 (1). doi:10.1186/s12968-019-0520-0. ISSN1532-429X.
Bhaskaran, Ashwin; Tung, Roderick; Stevenson, William G.; Kumar, Saurabh (2019). «Catheter Ablation of VT in Non-Ischaemic Cardiomyopathies: Endocardial, Epicardial and Intramural Approaches». Heart, Lung and Circulation28 (1): 84–101. doi:10.1016/j.hlc.2018.10.007. ISSN14439506.
